Literature DB >> 1856249

Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test.

S M Kelsey1, R C Hider, J R Bloor, D R Blake, C N Gutteridge, A C Newland.   

Abstract

Ferric maltol is a novel ferric iron compound with potential use as an oral therapy for iron deficiency anaemia. Using a single, low dose iron absorption test we compared absorption of ferric maltol with absorption of ferrous sulphate in 21 iron deficient subjects. Absorption of 10 mg of ferric maltol as either aqueous solution or a single tablet compared favourably with that of an equivalent dose of ferrous sulphate. At a higher, more therapeutic dose of 60 mg elemental iron as tablets, absorption of ferric maltol appeared to be both more rapid and total absorption greater, than that seen with ferrous sulphate. We conclude that iron from ferric maltol, both at low dose and higher, more therapeutic doses, is at least as well absorbed as from ferrous sulphate. Ferric maltol is the first ferric iron formulation to be absorbed to a degree equivalent to that of ferrous iron salts and may represent a viable form of administration for ferric iron in the treatment of iron deficiency anaemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1856249     DOI: 10.1111/j.1365-2710.1991.tb00292.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  8 in total

1.  Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Authors:  Bernd Bokemeyer; Annette Krummenerl; Christian Maaser; Stefanie Howaldt; Michael Mroß; Nick Mallard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  Clinical pharmacokinetics of ferric natural protein in iron-deficient females.

Authors:  A López de Ocáriz; M Simón; P Balsera; M Diaz; E García Quetglas; M Gimeno; P Coronel; J Honorato
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

4.  Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Authors:  C Schmidt; T Ahmad; Z Tulassay; D C Baumgart; B Bokemeyer; S Howaldt; A Stallmach; C Büning
Journal:  Aliment Pharmacol Ther       Date:  2016-05-29       Impact factor: 8.171

Review 5.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

6.  Evaluation of ferric and ferrous iron therapies in women with iron deficiency anaemia.

Authors:  Ilhami Berber; Halit Diri; Mehmet Ali Erkurt; Ismet Aydogdu; Emin Kaya; Irfan Kuku
Journal:  Adv Hematol       Date:  2014-06-11

7.  Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK.

Authors:  Jr Fraser Cummings; Aileen Fraser; Catherine Stansfield; Ian Beales; Shaji Sebastian; Sami Hoque
Journal:  BMJ Open Gastroenterol       Date:  2021-02

8.  Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Authors:  Stefanie Howaldt; Eugeni Domènech; Nicholas Martinez; Carsten Schmidt; Bernd Bokemeyer
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.